Icotrokinra had more significant improvements than placebo for multiple skin clearance measures following 16 weeks of treatment for plaque psoriasis in adolescents and adults. Icotrokinra is ...

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP).

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...

(Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in ...

Credit: MacroEcon/Shutterstock. Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral ...

(Nasdaq: LIPO) ("Lipella” or the "Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in ...

China: A recent study has found that in patients with Hashimoto's thyroiditis (HT), the presence of thyroid nodules, a higher FT3/FT4 ratio, and positive thyroglobulin antibodies were associated with ...

Improved targeting of the molecular drivers of psoriasis has paved the way for new oral therapies that offer the potential for major responses in a majority of patients. Identification of better ...

OBJECTIVE: In some diseases associated with inflammation, the C-reactive protein-to-albumin ratio can be used as a biomarker of inflammation. Since lichen planus is a chronic inflammatory disease, our ...